



19 June 2013

Company Announcements Office  
Australian Stock Exchange  
Level 6, 20 Bridge Street  
Sydney NSW 2000

### **Anteo Enters Into Feasibility Agreement**

**19 June 2013: Anteo Diagnostics Limited (ASX: ADO) ("Anteo")**, in compliance with its continuous disclosure obligations, announces that it has entered into an agreement for a Feasibility Study with a global healthcare company, to investigate and evaluate the potential of Mix&Go™. The objective of the Feasibility Study is to assess whether Mix&Go provides an advantage in the development of a new device. This will be determined by assessment of results generated by three scientists over twelve months. Depending on the outcome of the Study, and any commercial negotiations, Mix&Go may be utilised.

Anteo's Chief Executive Officer Dr Geoff Cumming commented, "We are delighted to have entered into this agreement and continue to focus our efforts on further commercialising Mix&Go. This contract is a step forward and the ongoing feedback we receive from discussions with a number of other interested parties continues to be encouraging."

ENDS

**For More Information Contact:**

**Dr Geoff Cumming, CEO**  
**Anteo Diagnostics Limited**  
**Tel: +61 2 8823 3110**

**Sam Sloane**  
**Six Degrees Investor Relations**  
**Tel: +61 2 9230 0661**

***Anteo Diagnostics Limited*** ABN 78 090 487 273  
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)

For personal use only